Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropathol Appl Neurobiol ; 41(1): 81-96, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25354646

ABSTRACT

Many different approaches to treating tauopathies are currently being explored, with a few compounds already in clinical development (including small molecules such as anti-aggregation compound LMTX and active vaccines AADvac1 and ACI-35). This review aims to summarize the status of the clinical candidates and to highlight the emerging areas of research that hold promise for drug development. Tau is post-translationally modified in several different ways (phosphorylated, acetylated, glycosylated and truncated). The extent of these modifications can be manipulated to influence tau aggregation state and pathogenesis and the enzymes involved provide tractable targets for drug intervention. In addition, modulation of tau expression levels is an attractive therapeutic approach. Finally, the recently described prion-like spreading of tau between cells opens up novel avenues from the tau drug development perspective. The review compares the merits of small-molecule and antibody-based therapies and emphasizes the need for amenable clinical biomarkers for drug development, particularly PET imaging.


Subject(s)
Drug Discovery , Tauopathies/drug therapy , tau Proteins/metabolism , Animals , Antibodies/therapeutic use , Clinical Trials as Topic , Humans , Immunotherapy , Protein Processing, Post-Translational , Tauopathies/therapy , tau Proteins/immunology
2.
Farmaco ; 56(1-2): 21-7, 2001.
Article in English | MEDLINE | ID: mdl-11347960

ABSTRACT

Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compounds potentially free of the drawbacks seen with peptidomimetic compounds so far. Synthetic optimization in two structural series focusing on improvement of potency, as well as on physicochemical properties and metabolic stability, has led to the identification of two candidate compounds 14 and 23. Both display potent and long-lasting blood pressure lowering effects in conscious sodium-depleted marmoset monkeys and double transgenic rats harboring both the human angiotensinogen and the human renin genes. In addition, 14 normalizes albuminuria and kidney tissue damage in these rats when given over a period of 4 weeks. These data suggest that treatment of chronic renal failure patients with a renin inhibitor might result in a significant improvement of the disease status.


Subject(s)
Antihypertensive Agents/pharmacology , Piperidines/pharmacology , Renin/antagonists & inhibitors , Animals , Blood Pressure/drug effects , Humans , Piperidines/chemical synthesis , Renal Insufficiency/drug therapy , Renin/pharmacology
3.
FEBS Lett ; 462(1-2): 135-9, 1999 Nov 26.
Article in English | MEDLINE | ID: mdl-10580106

ABSTRACT

A novel aspartic proteinase, called napsin, has recently been found in human and mouse. Due to high similarity with cathepsin D a structural model of human napsin A could be built. Based on this model a potential epitope SFYLNRDPEEPDGGE has been identified, which was used to immunize rabbits. The resulting antibody was employed in monitoring the expression of recombinant human napsin A in HEK293 cell line. Western blot analysis confirmed the specificity of the antibody and showed that human napsin A is expressed as a single chain protein with the molecular weight of approximately 38 kDa. Immunohistochemical studies revealed high expression levels of napsin A in human kidney and lung but low expression in spleen.


Subject(s)
Aspartic Acid Endopeptidases/analysis , Amino Acid Sequence , Antibodies/immunology , Aspartic Acid Endopeptidases/immunology , Aspartic Acid Endopeptidases/metabolism , Blotting, Western , Cells, Cultured , Epitopes , Humans , Immunohistochemistry , Kidney/enzymology , Lung/enzymology , Molecular Sequence Data , Sequence Homology, Amino Acid , Tissue Distribution
4.
Chem Biol ; 6(3): 127-31, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10074464

ABSTRACT

BACKGROUND: The aspartic proteinase renin catalyses the first and rate-limiting step in the conversion of angiotensinogen to the hormone angiotensin II, and therefore plays an important physiological role in the regulation of blood pressure. Numerous potent peptidomimetic inhibitors of this important drug target have been developed, but none of these compounds have progressed past clinical phase II trials. Limited oral bioavailability or excessive production costs have prevented these inhibitors from becoming new antihypertensive drugs. We were interested in developing new nonpeptidomimetic renin inhibitors. RESULTS: High-throughput screening of the Roche compound library identified a simple 3, 4-disubstituted piperidine lead compound. We determined the crystal structures of recombinant human renin complexed with two representatives of this new class. Binding of these substituted piperidine derivatives is accompanied by major induced-fit adaptations around the enzyme's active site. CONCLUSIONS: The efficient optimisation of the piperidine inhibitors was facilitated by structural analysis of the renin active site in two renin-inhibitor complexes (some of the piperidine derivatives have picomolar affinities for renin). These structural changes provide the basis for a novel paradigm for inhibition of monomeric aspartic proteinases.


Subject(s)
Aspartic Acid Endopeptidases/antagonists & inhibitors , Piperidines/pharmacology , Renin/antagonists & inhibitors , Fluorescein , Gene Library , Glutathione/metabolism , Histidine/metabolism , Humans , Protein Biosynthesis , Proteins/genetics , ras Proteins/metabolism
5.
J Neurochem ; 72(3): 1215-23, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10037494

ABSTRACT

Metalloprotease MP100 was originally isolated as a beta-secretase candidate from human brain using a beta-amyloid precursor protein (beta-APP)-derived p-nitroanilide (pNA) peptide substrate. Peptide sequences from purified MP100 were now found to resemble sequences reported for a puromycin-sensitive aminopeptidase (PSA) highly enriched in brain, and cDNA cloning revealed nearly complete homology of MP100 to PSA, with only a single bp difference resulting in an amino acid change at position 184. Another MP100 cDNA encoded a protein with a 36-amino acid deletion (positions 180-217) and a two-amino acid insertion after Val533. Purified recombinant human MP100 cleaved the original pNA substrate as well as a free beta-site-spanning amyloid beta (A beta) peptide (A beta(-10/+10)), generating A beta(1-10). The latter substrate, however, remained uncleaved, if N- and C-terminally blocked, and also purified beta-APP was not cleaved. Double immunoimaging revealed partial, patchy, colocalization of beta-APP and MP100 in doubly transfected human embryonic kidney cells (HEK cells) and in normal neuroblastoma cells, and both proteins could be coimmunoprecipitated from rat brain extracts, suggesting their close vicinity in vivo. Coexpression of MP100 and beta-APP695, however, did not boost A beta levels in HEK cells, although active enzyme was produced. Thus, MP100 does not exert true beta-secretase-like function in cells, although it may well act as a secondary exoprotease in a complex beta-APP/A beta metabolism.


Subject(s)
Brain/enzymology , Endopeptidases/metabolism , Amino Acid Sequence , Amyloid Precursor Protein Secretases , Amyloid beta-Protein Precursor/metabolism , Animals , Aspartic Acid Endopeptidases , Base Sequence , Cell Line , Cloning, Molecular , DNA, Complementary/genetics , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique, Indirect , Humans , Kidney/metabolism , Molecular Sequence Data , Precipitin Tests , Rats , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...